12.13.19
Residual cancer burden after neoadjuvant therapy can accurately predict breast cancer survival
Researchers from The University of Texas MD Anderson Cancer Center today reported results from a pooled analysis of more than 5,100 breast cancer patients that found residual cancer burden (RCB) continuous index and classification were independently and strongly prognostic for all breast cancer phenotypes. The study’s results were presented by W. Fraser Symmans, M.D., professor